Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 5,354 matching trials from the live ClinicalTrials.gov search.

Filters: Milwaukee, Wisconsin Clear all

Conditions: Tachyarrhythmia
Interventions: defibrillation lead; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 64
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 56 more

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis and Ureter Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis and Ureter Cancer AJCC v7, Stage III Ureter Cancer AJCC v7
Interventions: Biospecimen Collection, Clinical Observation, Computed Tomography, CT Urography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 913
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 571 more

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Ocrelizumab (US), Ocrelizumab (EU), ABP 692; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Mobile, Alabama • Scottsdale, Arizona • Carlsbad, California + 24 more

Conditions: Lupus Erythematosus, Systemic
Interventions: High-dose immunoablative therapy; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 3
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania • Milwaukee, Wisconsin

Conditions: Multiple Myeloma
Interventions: Teclistamab, Lenalidomide; Drug
Lead sponsor: European Myeloma Network B.V.; Network
Eligibility: 18 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 42
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Oral Cancer
Interventions: Oral Cavity Reconstruction; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Crohn's Disease
Interventions: Vedolizumab, Upadacitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Colorado Springs, Colorado + 12 more

Conditions: Peripheral Arterial Disease
Interventions: sodium nitrite; Drug
Lead sponsor: TheraVasc Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Aurora, Colorado • Atlanta, Georgia • Iowa City, Iowa + 6 more

Conditions: Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate; Radiation · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 5,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2021
U.S. locations: 210
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Conditions: ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute
Interventions: Marqibo; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 28
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 25 more

Conditions: End Stage Renal Disease, Renal Failure
Interventions: PAL-40 Active, PAL-40 Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years and older
Enrollment: 2,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 36
States / cities: Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more

Conditions: Fetal Bradycardia Complicating Labor and Delivery, Fetal Bradycardia During Labor, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus
Interventions: Half dose Oxytocin; Drug
Lead sponsor: Unyime Ituk; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 730 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Iowa City, Iowa • Milwaukee, Wisconsin

Conditions: Smoking
Interventions: varenicline, Individual smoking cessation counseling; Drug · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Aplastic Anemias, Hemoglobinopathies, Bone Marrow Failure
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 14
States / cities: Duarte, California • Gainesville, Florida • Atlanta, Georgia + 10 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Enzastaurin Hydrochloride, R-CHOP + placebo; Drug · Other
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more

Conditions: Telemedicine
Interventions: Custom Sound; Device
Lead sponsor: Cochlear; Industry
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Englewood, Colorado • Ann Arbor, Michigan • Chapel Hill, North Carolina + 1 more

Conditions: Hepatocellular Carcinoma
Interventions: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more

Conditions: Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions: Benralizumab 30 mg, Matched placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 15
States / cities: Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, tocilizumab [RoActemra/Actemra]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 76
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more

Conditions: Essential Tremor
Interventions: Pre-lemniscal Radiation Deep Brain Stimulation; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Osteoporosis
Interventions: ALX1-11 (drug); Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more

Conditions: Scleroderma, Systemic
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more

Conditions: Out of Hospital Cardiac Arrest
Interventions: Standard CPR, Continuous chest compressions; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 23,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 5
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania • Dallas, Texas + 2 more

Search by objective public record fields.

Lead Evaluation for Defibrillation and Reliability Post Approval Study

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

Homocysteine Study (HOST)

Oxytocin and Fetal Heart Rate Changes

Long-term Varenicline Treatment for Smoking Cessation

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

Safety and Efficacy of Remote Programming of Nucleus Cochlear Implants

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Pre-lemniscal Radiation Deep Brain Stimulation for ET

Open Label Extension Study of PREOS

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Continuous Chest Compressions vs AHA Standard CPR of 30:2